19243-30-2 Usage
Uses
Used in Pharmaceutical Industry:
22-Ketocholesterol is utilized as a precursor in the synthesis of steroidal hormones for pharmaceutical applications, given its role in the bioconversion process of cholesterol. Its unique structure allows for the development of drugs targeting specific hormonal imbalances or conditions.
Used in Research Applications:
In the field of biological and medical research, 22-Ketocholesterol is employed as a research tool to study the mechanisms of cholesterol conversion to steroidal hormones, as well as to investigate the effects of 22-KETOCHOLESTEROL on membrane properties and its potential role in various physiological processes.
Used in Diagnostics:
22-Ketocholesterol can be used as a biomarker in diagnostic assays to assess the metabolic state of cholesterol and the efficiency of the biosynthetic pathways leading to steroidal hormone production, which may be indicative of certain health conditions or diseases.
Used in Cosmetics Industry:
Due to its influence on membrane fluidity and permeability, 22-Ketocholesterol may be incorporated into cosmetic formulations to enhance skin health and integrity, potentially improving the delivery of other active ingredients in skincare products.
Check Digit Verification of cas no
The CAS Registry Mumber 19243-30-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,2,4 and 3 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 19243-30:
(7*1)+(6*9)+(5*2)+(4*4)+(3*3)+(2*3)+(1*0)=102
102 % 10 = 2
So 19243-30-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H10S3/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8,13-14H
19243-30-2Relevant articles and documents
Regulation of liver X receptor target genes by 22-functionalized oxysterols. Synthesis, in silico and in vitro evaluations
Viktorsson, Elvar ?rn,Gabrielsen, Mari,Kumarachandran, Nugalya,Sylte, Ingebrigt,Rongved, P?l,?strand, Ove Alexander H?gmoen,Kase, Eili Tranheim
, p. 119 - 127 (2017/01/13)
The endogenous oxysterol 22(R)-hydroxycholesterol (22RHC, 1) is an LXR agonist which upregulates genes of critical involvement in human cholesterol- and lipid metabolism. In contrast, its synthetic epimer 22(S)-hydroxycholesterol (22SHC, 8) has shown specific antagonistic effects in recent studies, avoiding unwanted side effects provided by potent LXR agonists. In terms of LXR modulation, the aim of this study was to compare 22SHC (8), 22RHC (1) and synthesized ligands with keto- and amide functionality in the 22nd position of the cholesterol scaffold. 22SHC (8) and 22RHC (1) performed as expected while 22-ketocholesterol (22KC, 10) revealed an attractive in vitro profile for further investigation in terms of anti-atherosclerotic properties as selective upregulation of the ATP-binding cassette transporter ABCA1 was observed. A new synthesized amide derivate, Fernholtz cyclohexylamide (13) was shown to reduce lipogenesis in a dose-responsive manner and abolish the effect of the potent LXR agonist T0901317 when administered simultaneously.
